Ensuring access to essential medicines in the developing countries: A framework for action

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 4, 2003, Pages 279-283

  Quick, Jonathan D ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ESSENTIAL DRUG;

DEVELOPING COUNTRY; DRUG COST; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; NOTE; PATENT; PRIORITY JOURNAL; PUBLIC HEALTH; WORLD HEALTH ORGANIZATION;

DEVELOPING COUNTRIES; DRUGS, ESSENTIAL; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; WORLD HEALTH ORGANIZATION;

EID: 0037384074     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00002-X     Document Type: Note

References (38)

1. World Health Organization. Global comparative pharmaceutical expenditures with related reference information. Health economics and drugs, Essential Drugs and Medicines Policy Series No.: 3 (EDM/PAR/2000.2). Geneva: World Health Organization; 2000.
2. World Health Organization. Progress of WHO Member States in developing national drug policies and in revising essential drugs lists (WHO/DAP/98.7). Geneva: World Health Organization; 1998.
3. Hogerzeil H. Promoting rational prescribing. Br J Clin Pharmacol 1995;39:1-6.
4. Quick JD, Rankin JR, Laing RO, O'Connor RW, Hogerzeil HV, Dukes MNG, et al, editors. Managing drug supply. 2nd ed. Chapter 29: Investigating drug use. West Hartford (CT): Kumarian Press; 1997. p. 437.
5. Hutin Y, Hauri A. Poor injection practices in health care setting two decades into the HIV pandemic: are we missing opportunities to prevent nosocomial HIV infections? [abstract]. In: Proceedings of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Barcelona: The Conference; 2002.
6. Homedes N, Ugalde A. Patients' compliance with medical treatments in the third world. What do we know? Health Policy Plann 1993;8:291-314.
7. World Health Organization. WHO medicines strategy: framework for action in Essential Drugs and Medicines Policy 2000-2003 (WHO/EDM/2000.1). Geneva: World Health Organization; 2000.
8. World Health Organization. The selection and use of essential medicines. Report of the Twelfth Meeting of the Expert Committee on the Selection and Use of Essential Medicines, April 2002. Technical report series No.: 914. Geneva: World Health Organization. In press 2003.
9. World Health Organization. WHO medicines strategy: 2000-2003. WHO policy perspectives on medicines No.: 1. Geneva: World Health Organization; 2000.
10. World Health Organization. Revised procedures for updating WHO's model list of essential drugs. Report by the secretariat (EB109/8). Geneva: World Health Organization; 2001.
11. Couper MC, Mehta D, editors. WHO model formulary. Geneva: World Health Organization; 2002.
12. WHO medicines Web site. Available at: http://www.who.int/medicines/. Accessed Nov 5, 2002.
13. Management Sciences for Health in collaboration with WHO. International drug price indicator guide. Boston (MA): Management Sciences for Health; 2001.
14. United Nations Children's Fund, Joint United Nations Programme on HIV/AIDS, World Health Organization, and Médecins Sans Frontières. Sources and prices of selected drugs and diagnostics for people living with HIV/AIDS. Geneva: World Health Organization; 2002.
15. International Trade Centre. Pharmaceutical starting materials/essential drugs report. Geneva: International Trade Centre/United Nations Conference on Trade and Development/World Trade Organization.
16. World Health Organization. AFRO essential drugs price indicator. Brazzaville: World Health Organization Regional Office for Africa.
17. Antiretrovirals in Latin America and the Caribbean. Pan American Health Organization Web site. Available at: http://www.paho.org/English/HCP/HCA/antiretrovirals_HP.htm. Accessed Nov 5, 2002.
18. Caves RE, Whinston MD, Hurwitz MA. Patent expiration, entry, and competition in the US pharmaceutical industry. Brookings Papers on Economic Activity 1991, special issue, 1-62.
19. World Health Organization. World pharmaceutical situation. Geneva: World Health Organization. In press 2003.
20. World Health Organization. Public-private roles in the pharmaceutical sector. Implications for equitable access and rational drug use. Health economics and drugs, Essential Drugs and Medicines Policy Series No.: 5 (WHO/DAP/97.12). Geneva: World Health Organization; 1997.
21. Scherer FM, Watal J. Post-TRIPS options for access to patented medicines in developing countries. Commission on Macroeconomics and Health Working Paper Series, Paper for Working Group 4. 2001.
22. Commission on Intellectual Property Rights. Integrating intellectual property rights and development policy. Report of the Commission on Intellectual Property Rights. London: Department for International Development; 2002.
23. World Health Organization (WHO)/World Trade Organization (WTO) report of the workshop on differential pricing and financing of essential drugs; April 8-11, 2001; Hosbjor, Norway. Geneva: World Health Organization; 2001.
24. Creese A, Quick J. Differential pharmaceutical pricing - arrangements and feasibility [WHO/EDM discussion paper]. Department of Essential Drugs and Medicines Policy. Geneva: World Health Organization; 2002.
25. Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001.
26. Pérez-Casas C, Herranz E, Ford N. Pricing of drugs and donations: options for sustainable equity pricing. Trop Med Int Health 2001;6:960-4.
27. World Health Organization. Globalization, TRIPS and access to pharmaceuticals. WHO policy perspectives on medicines No.: 3. Geneva: Word Health Organization; 2001.
28. Gorecki PK. Regulating the price of prescription drugs in Canada: compulsory licensing, product selection, and government reimbursement programs. Technical report No.: 8. Ottawa: Economic Council of Canada; 1981.
29. World Trade Organization Ministerial Conference, Fourth Session; Nov 9-14, 2001; Doha, Qatar [WT/MIN(01)/DEC/W/2 14 November 2001].
30. World Health Organization. Health reform and drug financing: selected topics. Health economics and drugs, EDM series No.: 6 (WHO/DAP/98.3). Geneva: World Health Organization; 1998.
31. Zerda A, Velasquez G, Tobar F, Vargus JE. Health insurance and access to medicines. Washington: World Health Organization; 2002.
32. Global Fund to Fight Aids, Tuberculosis and Malaria. Available at: http://www.globalfundatm.org. Accessed Nov 11, 2002.
33. Quick JD, Rankin JR, Laing RO, O'Connor RW, Hogerzeil HV, Dukes MNG, et al, editors. Managing drug supply. West Hartford (CT): Kumarian Press; 1997. p. 68-88.
34. World Health Organization. Highlights of the year 2000 in Essential Drugs and Medicines Policy (WHO/EDM/2001.4). Geneva: World Health Organization; 2000.
35. World Health Organization. Effective drug regulation: what can countries do? (WHO/HTP/EDM/MAC(11)/99.6). Geneva: World Health Organization; 1999.
36. Ratanawijitrasin S, Wondemagegnehu E. Effective drug regulation - a multi-country study. Geneva: World Health Organization; 2002.
37. World Health Organization. Basic training modules on GMP [CD]. Geneva: World Health Organization; 2002.
38. World Health Organization. Counterfeit drugs: guidelines for the development of measures to combat counterfeit drugs (WHO/EDM/QSM/99.1). Geneva: World Health Organization; 1999.